Asprosin-neutralizing antibodies as a treatment for metabolic syndrome

Asprosin-neutralizing antibodies as a treatment for metabolic syndrome

Background: Recently, we discovered a new glucogenic and centrally acting orexigenic hormone – asprosin. Asprosin is elevated in metabolic syndrome (MS) patients, and its genetic loss results in reduced appetite, leanness, and blood glucose burden, leading to protection from MS. Methods: We generate...

Full description

Bibliographic Details
Main Authors: Ila Mishra, Clemens Duerrschmid, Zhiqiang Ku, Yang He, Wei Xie, Elizabeth Sabath Silva, Jennifer Hoffman, Wei Xin, Ningyan Zhang, Yong Xu, Zhiqiang An, Atul R Chopra
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2021-04-01
Series:eLife
Subjects:
asprosin
obesity
pharmacokinetics
pharmacodynamics
metabolic syndrome
therapeutic monoclonal antibodies
Online Access:https://elifesciences.org/articles/63784

Internet

https://elifesciences.org/articles/63784

Similar Items